BioPharmaSpec Expands with Three New European Sites to Enhance Biopharmaceutical Services

• BioPharmaSpec announces the opening of three new European facilities in Freiburg, Bergamo, and Vilnius, set to enhance its discovery and R&D services for biopharmaceutical characterization.

• The new labs will offer advanced analytical services, including structural and physicochemical characterization for monoclonal antibodies, antibody-drug conjugates, and other biologics.

BioPharmaSpec, a Contract Research Organization (CRO) specialising in the discovery and preclinical characterization of biopharmaceuticals, has announced the opening of three new European facilities. The sites, located in Freiburg, Bergamo, and Vilnius, will support the company’s growing global client base by offering cutting-edge services for the characterization of a wide range of biopharmaceuticals.

Set to open in January 2025, these new laboratories will focus on structural and physicochemical characterization, catering to products such as monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapy products, bioactive peptides, oligonucleotides, and carbohydrates. They will also support HCP identification and the quantification of other product- and process-related impurities. This expansion complements BioPharmaSpec’s existing UK and US operations, further strengthening its position in the global biopharmaceutical market.

The expansion is a key milestone in BioPharmaSpec’s rapid growth since its founding in 2014. The company was established by Professor Howard R. Morris, a pioneer in mass spectrometry, and Dr. Andrew Reason, a specialist in analytical method commercialization. BioPharmaSpec has quickly gained recognition for its advanced services, which help accelerate the development of biopharmaceutical drug pipelines.

Professor Morris, the founder of BioPharmaSpec, expressed pride in overseeing the expansion, commenting, “It has been a privilege to help drive forward this exciting development and significant expansion of BioPharmaSpec.” He added that the new European facilities will enhance the company’s ability to serve the global biopharmaceutical industry, which increasingly relies on high-quality analytical services.

Lindsay McGowan, Director of Business Development at BioPharmaSpec, highlighted the strategic importance of the new facilities. “With the opening of these new laboratories and the recruitment of local expert scientists, we are strategically and uniquely placed to provide our expanding global client base with the highest levels of technical and customer service,” she stated.

The new labs will be equipped with state-of-the-art instrumentation, including Waters Select Series CYCLIC Ion Mobility Separation (IMS) High Definition LC-MS/MS and SCIEX ZenoTOF 7600 LC-MS/MS with EAD. These advanced tools will allow BioPharmaSpec to provide its clients with precise and reliable analytical results, helping to drive the development of next-generation therapies.